Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics for $820 million to obtain worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis D virus (HDV). The deal expands Mirum’s rare liver disease portfolio and brings an asset currently in a global Phase 3 AZURE program with top‑line data expected in 2H 2026. Bluejay’s brelovitug demonstrated robust antiviral activity in Phase 2, including HDV RNA responses and improved liver enzymes, with an acceptable safety profile. Mirum framed the acquisition as complementary to its existing liver disease expertise and said the transaction accelerates their rare‑disease strategy. The structured payment includes cash, stock and milestone potential; Mirum expects to leverage its regulatory and commercial experience to advance brelovitug toward registrational filings and potential 2027 launches if Phase 3 readouts are positive.